Welcome to our dedicated page for 111 SEC filings (Ticker: YI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking China’s fast-moving digital pharmacy sector is tough. 111 Inc.’s filings weave together health-care regulation, e-commerce logistics and AI investment—leaving investors hunting through dense disclosures for the real story. If you’ve ever asked, “How do I find 111 Inc. insider trading Form 4 transactions or break down its quarterly margins?” you’re in the right place.
Stock Titan turns each document into usable insight. Our AI reads every 10-K, 10-Q and 8-K the moment it hits EDGAR, then delivers clear answers to common searches like “111 Inc. quarterly earnings report 10-Q filing” or “111 Inc. proxy statement executive compensation.”
- Real-time alerts for 111 Inc. Form 4 insider transactions real-time—spot executive stock moves before the market reacts.
- 111 Inc. annual report 10-K simplified—see revenue split between B2B drug distribution and B2C pharmacy sales without wading through footnotes.
- 111 Inc. 8-K material events explained—whether it’s a new hospital partnership or regulatory update, our summaries tell you why it matters.
Need deeper context? Ask a plain-English question—“understanding 111 Inc. SEC documents with AI” or “111 Inc. earnings report filing analysis”—and the platform highlights key risk factors, segment KPIs and cash-flow swings in seconds. From 111 Inc. executive stock transactions Form 4 to payment-cycle trends hidden inside footnotes, our expert layer makes complexity manageable.
Stop scrolling through hundreds of pages. Get 111 Inc. SEC filings explained simply—and make faster, better-informed decisions today.
Sinclair, Inc. (SBGI) – Insider Transaction Summary
On 20 June 2025 Sinclair, Inc. filed a Form 4 reporting that director Daniel C. Keith acquired 18,084 shares of the company’s Class A common stock on 06 June 2025. The transaction was coded “A,” indicating an acquisition, and the accompanying footnote clarifies that the shares were issued pursuant to the company’s Stock Incentive Plan.
As a result of this grant, Mr. Keith’s direct beneficial ownership increased to 67,027 shares. No dispositions, derivative security exercises, or indirect holdings were disclosed in the filing, and no transaction price was stated. The Form 4 was signed by Anastasia Thomas Nardangeli, Esq. under a Power of Attorney on Mr. Keith’s behalf.
Because the filing shows additional equity awarded to a sitting director, it may be viewed as a modest affirmation of long-term alignment between the board and shareholders. However, the absence of valuation details or performance conditions limits immediate assessment of the grant’s economic impact.
FAQ
What is the current stock price of 111 (YI)?
What is the market cap of 111 (YI)?
What is the core business model of 111 Inc.?
How does 111 Inc. generate revenue?
What key services does 111 Inc. provide?
How is technology integrated into 111 Inc.'s operations?
How does 111 Inc. differentiate itself in the healthcare market?
What role do strategic partnerships play for 111 Inc.?
What types of products are part of 111 Inc.'s portfolio?
